We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.63B
AUM Growth
-$447M
Cap. Flow
-$292M
Cap. Flow %
-11.12%
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$30.1M
2
SRRK icon
Scholar Rock
SRRK
+$23.3M
3
THC icon
Tenet Healthcare
THC
+$19.2M
4
FOLD
Amicus Therapeutics
FOLD
+$14M
5
JANX icon
Janux Therapeutics
JANX
+$10.8M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$67.2M
2
HUM icon
Humana
HUM
+$46.9M
3
EXAS
Exact Sciences
EXAS
+$43.4M
4
ALGN icon
Align Technology
ALGN
+$29.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Consumer Staples 1.85%
3 Financials 0.14%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.95B
$15.5M 0.59%
471,086
-228,303
-33% -$10.7M
ACRS icon
52
Aclaris Therapeutics
ACRS
$867M
$15.4M 0.59%
6,204,309
+3,450,814
+125% +$8.59M
CRNX icon
53
Crinetics Pharmaceuticals
CRNX
$8.93B
$15M 0.57%
294,100
+4,700
+2% +$263K
PHVS icon
54
Pharvaris
PHVS
$2.43B
$14.9M 0.57%
775,131
+18,200
+2% +$375K
AGL icon
55
Agilon Health
AGL
$1.63B
$14.2M 0.54%
298,532
-65,340
-18% -$3.95M
OSCR icon
56
Oscar Health
OSCR
$8.54B
$14.1M 0.54%
1,050,000
+38,600
+4% +$621K
SWTX
57
DELISTED
SpringWorks Therapeutics
SWTX
$11.9M 0.45%
328,911
+129,056
+65% +$4.51M
DYN icon
58
Dyne Therapeutics
DYN
$4.95B
$11.2M 0.43%
474,528
+13,500
+3% +$399K
JANX icon
59
Janux Therapeutics
JANX
$1B
$10.9M 0.42%
+204,466
New +$10.8M
INZY
60
DELISTED
Inozyme Pharma
INZY
$10.7M 0.41%
3,861,983
+59,100
+2% +$225K
NMRA icon
61
Neumora Therapeutics
NMRA
$300M
$10.1M 0.39%
955,106
+127,005
+15% +$1.52M
JSPR icon
62
Jasper Therapeutics
JSPR
$26.6M
$9.9M 0.38%
463,088
+4,000
+0.9% +$83.3K
ELVN icon
63
Enliven Therapeutics
ELVN
$4.35B
$9.64M 0.37%
428,571
– –
XNCR icon
64
Xencor
XNCR
$1.6B
$9.22M 0.35%
401,013
– –
CGEM icon
65
Cullinan Oncology
CGEM
$1.18B
$9.04M 0.34%
742,114
+5,200
+0.7% +$74.7K
PRTA icon
66
Prothena Corp
PRTA
$468M
$8.93M 0.34%
644,601
+19,553
+3% +$308K
CMPX icon
67
Compass Therapeutics
CMPX
$400M
$8.38M 0.32%
5,779,575
+150,336
+3% +$250K
BCAX
68
Bicara Therapeutics
BCAX
$1.82B
$7.77M 0.3%
445,975
– –
ARDX icon
69
Ardelyx
ARDX
$997M
$7.42M 0.28%
+1,463,629
New +$8.09M
ZBIO
70
Zenas BioPharma
ZBIO
$2.02B
$7.2M 0.27%
878,667
– –
BEAM icon
71
Beam Therapeutics
BEAM
$2.82B
$6.26M 0.24%
252,223
+2,300
+0.9% +$58.7K
TARS icon
72
Tarsus Pharmaceuticals
TARS
$2.97B
$6.14M 0.23%
+110,889
New +$5.04M
NVRO
73
DELISTED
NEVRO CORP.
NVRO
$6.13M 0.23%
1,648,100
+266,600
+19% +$1.23M
SLNO
74
DELISTED
Soleno Therapeutics
SLNO
$5.58M 0.21%
+124,095
New +$6.43M
PLRX icon
75
Pliant Therapeutics
PLRX
$64.4M
$5.33M 0.2%
404,796
+19,800
+5% +$270K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rock Springs Capital Management held 119 positions worth $2.63B, down 15% from $3.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $292M in Q4 2024, closing 12 positions and reducing 30 holdings. Its most notable exit was Humana, an estimated $46.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Scholar Rock worth $31M.

  • Rock Springs Capital Management's largest Q4 2024 buy was Scholar Rock: 716,782 shares worth $31M.
  • Rock Springs Capital Management added most to Blueprint Medicines in Q4 2024, an estimated $30.1M increase.
  • Rock Springs Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $67.2M.
  • Rock Springs Capital Management fully exited Humana in Q4 2024, selling an estimated $46.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $2.63B portfolio in Q4 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 12 in Q4 2024.
  • Rock Springs Capital Management's portfolio value fell 15% quarter-over-quarter to $2.63B.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.